• F1 Oncology Expands Operations contractpharma
    November 18, 2018
    Shanghai EXUMA will develop these clinical programs into multicenter trials under a centralized regulatory pathway based on the results of investigator-initiated trials (IITs) of CAR-T therapies for the treatment of metastatic renal cell carcinoma (mRCC)
PharmaSources Customer Service